Peripheral Artery Disease (PAD)

This channel includes news, interventions, and new technology innovations for peripheral artery diease, PAD and critical limb ischemia. 

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020

March 28, 2020 — People with symptomatic...

Medicare, CMS, calls for cancelling or postponing all elective or non-essential medical procedures, test and surgeries due to COVID-19. #COVID19 #SARcov2 #coronavirus #cardiology
Feature | Coronavirus (COVID-19) | March 20, 2020 | Dave Fornell, Editor
A CSI Diamondabck 360 atheretectomy system in use during a cath lab procedure at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A CSI Diamondabck 360 atheretectomy system in use during a cath lab procedure at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Atherectomy Devices | February 13, 2020

February 13, 2020 — The U.S. Food and Drug Administration (FDA) has issued its final guidance on "Peripheral...

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | February 11, 2020 | Saloni Walimbe

Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from...

The most popular content in the month of November on DAIC was by far the data from the late-breaking trials from the American Herart Association (AHA) 2019 meeting. The second item on this month's list is an overview of key heart failure takeaways from AHA by Nasrien Ibrahim, M.D., associate director of resynchronization and advanced cardiac therapeutics at Massachusetts General Hospital.  Photo by Scott Morgan/AHA.

The most popular content in the month of November on DAIC was by far the data from the late-breaking trials from the American Herart Association (AHA) 2019 meeting. The second item on this month's list is an overview of key heart failure takeaways from AHA by Nasrien Ibrahim, M.D., associate director of resynchronization and advanced cardiac therapeutics at Massachusetts General Hospital.  Photo by Scott Morgan/AHA. 

Feature | December 17, 2019

December 16, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (...

The FDA cleared the IN.PACT AV drug-coated Balloon. Clinical data shows In.Pact AV DCB is Safe, reduces reinterventions and maintains access for end-stage renal disease patients undergoing dialysis
News | November 26, 2019

November 21, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated...

News | Peripheral Artery Disease (PAD) | November 14, 2019

November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical...

News | Peripheral Artery Disease (PAD) | November 14, 2019

November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded...

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot.  #VIVA #VIVA19 #VIVA2019

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot. 

News | Peripheral Artery Disease (PAD) | November 14, 2019

November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the...

The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the Medtronic IN.PACT AV Access drug-coated balloon (DCB) met both of its endpoints, in data presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting. #VIVA #VIVA19 #VIVA2019

The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the Medtronic IN.PACT AV Access drug-coated balloon (DCB) met both of its endpoints, in data presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting.

 

News | Drug-Eluting Balloons | November 14, 2019

November 7, 2019 — The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of...

The Rex Medical Revolution rotational atherectomy system incorporates continuous aspiration and has a dual indication for atherectomy and thrombectomy.  #VICA19 #VIVA2019

The Rex Medical Revolution rotational atherectomy system incorporates continuous aspiration and has a dual indication for atherectomy and thrombectomy. 

News | Atherectomy Devices | November 11, 2019

November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and...

The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study. #VIVA #VIVA19 #VIVA2019

The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study.

News | Stents Carotid | November 11, 2019

November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard...

 Bioresorbable stent Abbott Absorb stent
News | November 08, 2019

November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients...

News | Stents Bioresorbable | November 07, 2019

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was...

In.Pact Admiral drug-coated balloon (DCB). #VIVA #VIVA19 #VIVA2019

The In.Pact Admiral drug-coated balloon.

News | Drug-Eluting Balloons | November 07, 2019

November 7, 2019 — Real-world, four-year study results of the In.Pact Admiral drug-coated balloon (DCB) demonstrate...

Overlay Init